次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

がんプロファイリングの世界市場:技術別、がんタイプ別2024年予測

Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024

出版元:MarketsandMarketsLinkIcon出版元について
発行年:2019年6月
定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文224ページになります。
商品コード:MAM1592

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
がんプロファイリングの世界市場規模は2019年の推計75億ドルから、今後2024年には124億ドル市場へと拡大が見込まれます。当レポートでは、2024年に至るがんプロファイリングの世界市場予測(市場規模US$)、技術別市場(免疫測定、次世代シーケング、ポリメラーゼ連鎖反応、in situハイブリダイゼーション、マイクロアレイ、マススペクトロメトリー、その他)、がんタイプ別市場(乳がん、肺がん、結腸直陽がん、前立腺がん、メラノーマ、その他)、バイオマーカータイプ別市場(遺伝子、タンパク質、その他)、用途別市場(研究各種、臨床各種)、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業12社プロフィール動向などの情報も交えて、がんプロファイリング市場の現在と今後展開を予測分析していきます。

【レポート構成概要】
◆がんプロファイリングの世界市場予測2017-2024年
・市場規模(US$)

◆技術別、市場-2024年
・免疫測定
・次世代シーケンシング(NGS)
・ポリメラーゼ連鎖反応(PCR)
・in situハイブリダイゼーション(ISH)
・マイクロアレイ
・マススペクトロメトリー
・その他技術
※(市場規模US$) 

◆がんタイプ別、市場-2024年
・乳がん
・肺がん
・結腸直腸がん
・前立腺がん
・メラノーマ
・その他がんタイプ
※(市場規模US$) 

◆バイオマーカータイプ別、市場-2024年
・遺伝子バイオマーカー
・タンパク質バイオマーカー
・その他バイオマーカー
※(市場規模US$) 

◆用途別、市場-2024年
研究
・バイオマーカー探索
・パーソナル医療
臨床
・診断
・予後診断
・モニタリング、治療
・スクリーニング
※(市場規模US$)

◆主要国地域別市場-2024年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
中南米
中東アフリカ
※国地域別に全セグメントの細分化データ掲載、詳細は目次参照

◆市場分析
・市場ダイナミクス分析(ドライバー、障壁、機会、課題)
・競合状況

◆がんプロファイリングの主要企業プロフィール動向
・ILLUMINA, INC.          
・QIAGEN N.V. 
・NEOGENOMIC LABORATORIES, INC. 
・シスメックス株式会社   
・HTG MOLECULAR DIAGNOSTICS, INC.           
・HELOMICS CORPORATION    
・GENOMIC HEALTH, INC.        
・CARIS LIFE SCIENCES
・NANOSTRING TECHNOLOGIES, INC. 
・RIBOMED BIOTECHNOLOGIES, INC.  
・GUARDANT HEALTH, INC.     
・FOUNDATION MEDICINE
(全224頁)



【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Cancer/Tumor Profiling Market by Technology (Immunoassay, NGS, PCR, In Situ Hybridization), Cancer Type (Breast, Lung, Colorectal), Biomarker Type (Genomic Biomarkers, Protein Biomarkers), Application (Diagnostics, Prognostics) - Global Forecast to 2024

Table of Contents

1.... Introduction

1.1            OBJECTIVES OF THE STUDY
1.2            MARKET DEFINITION
1.3            MARKET SCOPE
1.3.1.1             MARKETS COVERED
1.3.1.2             YEARS CONSIDERED FOR THE STUDY
1.4            CURRENCY
1.5            STAKEHOLDERS
1.6            LIMITATIONS

2.... RESEARCH METHODOLOGY. 22

2.1            RESEARCH APPROACH
2.1.1               SECONDARY RESEARCH
2.1.1.1             KEY DATA FROM SECONDARY SOURCES
2.1.2               PRIMARY RESEARCH
2.1.2.1             KEY DATA FROM PRIMARY SOURCES
2.1.2.2             BREAKDOWN OF PRIMARIES
2.1.2.3             KEY INDUSTRY INSIGHTS
2.2            MARKET SIZE ESTIMATION
2.3            DATA TRIANGULATION APPROACH
2.4            ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1            CANCER/TUMOR PROFILING: MARKET OVERVIEW
4.2            CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.3            REGIONAL MIX: CANCER/TUMOR PROFILING MARKET  (2019–2024)
4.4            CANCER/TUMOR PROFILING MARKET: DEVELOPED VS. DEVELOPING MARKETS (2019 VS. 2024)

5.... MARKET OVERVIEW

5.1            INTRODUCTION
5.2            MARKET DYNAMICS
5.2.1               MARKET DRIVERS
5.2.1.1             INCREASING INCIDENCE OF CANCER
5.2.1.2             INCREASING USE OF BIOMARKERS IN CANCER PROFILING
5.2.1.3             INCREASING CANCER RESEARCH AND FUNDING
5.2.1.4             TECHNOLOGICAL ADVANCEMENTS
5.2.2               MARKET RESTRAINTS
5.2.2.1             HIGH CAPITAL INVESTMENT
5.2.2.2             TECHNICAL ISSUES WITH SAMPLE COLLECTION AND STORAGE
5.2.3               MARKET OPPORTUNITIES
5.2.3.1             INCREASING DEMAND FOR PERSONALIZED MEDICINE
5.2.3.2             GROWING NEED FOR POINT-OF-CARE DIAGNOSTICS
5.2.4               MARKET CHALLENGES
5.2.4.1             LOW BIOMARKER DISCOVERY-TO-APPROVAL RATIO
5.2.4.2             POOR REGULATORY AND REIMBURSEMENT SCENARIO

6.... INDUSTRY INSIGHTS

6.1            INTRODUCTION
6.2            INDUSTRY TRENDS
6.2.1               INTEGRATION OF OMICS DATA
6.2.2               ADVANCES IN LIQUID BIOPSY
6.2.3               ORGANOIDS FOR PERSONALIZED MEDICINE

7.... CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

7.1            INTRODUCTION
7.2            IMMUNOASSAYS
7.2.1               IMMUNOASSAY TESTS IDENTIFY AND ASSESS THE PROGRESSION OF DISEASE, THEREBY PROVIDING INFORMATION VITAL FOR BETTER THERAPEUTIC CHOICES
7.3            NEXT-GENERATION SEQUENCING
7.3.1               ADVANCES IN NGS MULTIPLEXING CAPABILITIES ENABLE ONE ASSAY TO PROVIDE A COMPLETE TUMOR MOLECULAR PROFILE
7.4            POLYMERASE CHAIN REACTION
7.4.1               REAL-TIME PCR HELPS IN THE QUANTIFICATION OF LOW-COPY TRANSCRIPTS, AIDING BIOMARKER IDENTIFICATION
7.5            IN SITU HYBRIDIZATION
7.5.1               FISH IS THE GOLD STANDARD FOR EVALUATING SOME KEY BIOMARKERS AND PLAYS A CRITICAL ROLE IN GUIDING TARGETED THERAPIES
7.6            MICROARRAYS
7.6.1               MICROARRAYS ARE WIDELY ADOPTED IN DIAGNOSTICS AS THEY AID IN PREDICTING THE RECURRENCE OF CANCER AFTER TREATMENT
7.7            MASS SPECTROMETRY
7.7.1               TECHNOLOGICAL ADVANCEMENTS ARE SUPPORTING THE ADOPTION OF THIS TECHNOLOGY FOR SENSITIVE, RELIABLE, AND RAPID DIAGNOSIS. 62
7.8            OTHER TECHNOLOGIES. 63


8.... CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE

8.1            INTRODUCTION
8.2            BREAST CANCER
8.2.1               BREAST CANCER IS THE MOST COMMON CANCER FOUND AMONG WOMEN
8.3            LUNG CANCER
8.3.1               MOLECULAR CHARACTERIZATION OF TUMORS USING NGS HAS IS A KEY TOOL FOR THE CLINICAL MANAGEMENT OF NSCLC PATIENTS
8.4            COLORECTAL CANCER
8.4.1               IHC, PCR, MICROARRAYS, AND IMAGING TECHNOLOGIES ARE MAJOR TECHNOLOGIES USED IN COLORECTAL DIAGNOSTICS
8.5            PROSTATE CANCER
8.5.1               PROSTATE-SPECIFIC ANTIGEN IS A WIDELY USED FDA-APPROVED BIOMARKER FOR PROSTATE CANCER SCREENING
8.6            MELANOMA
8.6.1               RT-QPCR IS GENERALLY UTILIZED TO CONDUCT MOLECULAR PROFILING AND ANALYZE BIOMARKERS IN MELANOMAS
8.7            OTHER CANCERS

9.... CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE

9.1            INTRODUCTION
9.2            GENETIC BIOMARKERS. 79
9.2.1               GENETIC BIOMARKERS ARE FREQUENTLY USED IN CLINICAL PRACTICE FOR DIAGNOSIS AND PROGNOSIS
9.3            PROTEIN BIOMARKERS. 80
9.3.1               PROTEOMIC METHODS SHOWCASE SIGNIFICANT PROMISE FOR THE DISCOVERY OF NOVEL BIOMARKERS
9.4            OTHER BIOMARKERS

10.. CANCER/TUMOR PROFILING MARKET, BY APPLICATION

10.1          INTRODUCTION
10.2          RESEARCH APPLICATIONS
10.2.1             BIOMARKER DISCOVERY
10.2.1.1           BIOMARKERS ARE BEING EXPLOITED FOR THE DEVELOPMENT OF PERSONALIZED OR PRECISION MEDICINE
10.2.2             PERSONALIZED MEDICINE
10.2.2.1           THE FIELD OF PERSONALIZED MEDICINE IS WITNESSING RAPID GROWTH IN THE AREA OF ONCOLOGY
10.3          CLINICAL APPLICATIONS
10.3.1             DIAGNOSTICS
10.3.1.1           TUMOR PROFILING IS RAPIDLY GAINING MOMENTUM IN THE AREA OF DIAGNOSTICS
10.3.2             PROGNOSTICS
10.3.2.1           ADVANCEMENTS IN MOLECULAR BIOLOGY ARE AIDING THE UPTAKE OF TUMOR PROFILING IN THIS SEGMENT

10.3.3             MONITORING & TREATMENT
10.3.3.1           MULTIPLATFORM PROFILING ANALYSES ARE GAINING RECOGNITION FOR MONITORING AND TREATMENT AMONG CANCER PATIENTS
10.3.4             SCREENING
10.3.4.1           SCREENING TESTS HELP IN DECIDING IF DIAGNOSTIC TESTS ARE REQUIRED BY THE PATIENT

11.. CANCER/TUMOR PROFILING MARKET, BY REGION

11.1          INTRODUCTION
11.2          NORTH AMERICA
11.2.1             US
11.2.1.1           US DOMINATES THE NORTH AMERICAN CANCER/TUMOR PROFILING MARKET
11.2.2             CANADA
11.2.2.1           GROWING PUBLIC-PRIVATE PARTNERSHIPS TO PROMOTE PROTEOMICS RESEARCH ARE EXPECTED TO DRIVE THE MARKET IN CANADA
11.3          EUROPE
11.3.1             GERMANY
11.3.1.1           ADVANCEMENTS PROTEOMICS AND GENOMICS RESEARCH ARE EXPECTED TO DRIVE MARKET GROWTH
11.3.2             UK
11.3.2.1           GROWTH IN THE LIFE SCIENCE INDUSTRY AND THE INCREASE IN ACADEMIA-INDUSTRY PARTNERSHIPS WILL BE THE KEY FACTORS DRIVING THE MARKET
11.3.3             FRANCE
11.3.3.1           GROWTH IN THIS MARKET IS PRIMARILY DRIVEN BY INCREASING INVESTMENTS IN LIFE SCIENCE R&D FOR INFRASTRUCTURAL DEVELOPMENT
11.3.4             ITALY
11.3.4.1           INCREASING INVESTMENT IN CANCER AND TRANSLATIONAL RESEARCH IS EXPECTED TO PROPEL MARKET GROWTH DURING THE FORECAST PERIOD
11.3.5             SPAIN
11.3.5.1           RISING INCIDENCE OF CANCER AND INCREASING FOCUS ON CANCER BIOMARKERS BY VARIOUS MEDICAL SOCIETIES TO SUPPORT MARKET GROWTH IN SPAIN
11.3.6             REST OF EUROPE
11.4          ASIA PACIFIC
11.4.1             JAPAN
11.4.1.1           LARGE NUMBER OF RESEARCH INITIATIVES TOWARDS THE DEVELOPMENT OF PRECISION MEDICINE SUPPORTING MARKET GROWTH IN JAPAN
11.4.2             CHINA
11.4.2.1           CHINA HAS THE FASTEST-GROWING RESEARCH SECTOR IN THE APAC REGION
11.4.3             INDIA
11.4.3.1           INCREASING PHARMA R&D AND GOVERNMENT FUNDING IN THE BIOTECHNOLOGY INDUSTRY ARE THE MAJOR FACTORS DRIVING MARKET GROWTH IN INDIA
11.4.4             REST OF ASIA PACIFIC

11.5          LATIN AMERICA
11.5.1             GROWING PROTEOMICS RESEARCH IN THE FIELD OF CANCER ALONG WITH THE RISING USE OF ADVANCED TECHNIQUES TO DRIVE MARKET GROWTH.. 148
11.6          MIDDLE EAST & AFRICA
11.6.1             GROWING GENOMICS AND PROTEOMICS RESEARCH AND INCREASING RESEARCH COLLABORATIONS ARE EXPECTED TO SUPPORT MARKET GROWTH

12.. COMPETITIVE LANDSCAPE

12.1          OVERVIEW
12.2          COMPETITIVE LEADERSHIP MAPPING
12.2.1             VISIONARY LEADERS
12.2.2             INNOVATORS
12.2.3             DYNAMIC DIFFERENTIATORS
12.2.4             EMERGING COMPANIES
12.3          COMPETITIVE SITUATION AND TRENDS
12.3.1             PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS. 158
12.3.2             EXPANSIONS
12.3.3             ACQUISITIONS
12.3.4             OTHER STRATEGIES

13.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW)*
13.1          ILLUMINA, INC.
13.2          QIAGEN N.V.
13.3          NEOGENOMIC LABORATORIES, INC.
13.4          SYSMEX CORPORATION. 181
13.5          HTG MOLECULAR DIAGNOSTICS, INC.
13.6          HELOMICS CORPORATION. 191
13.7          GENOMIC HEALTH, INC. 195
13.8          CARIS LIFE SCIENCES. 198
13.9          NANOSTRING TECHNOLOGIES, INC.
13.10       RIBOMED BIOTECHNOLOGIES, INC.
13.11       GUARDANT HEALTH, INC.
13.12       FOUNDATION MEDICINE. 209
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.

14.. APPENDIX

LIST OF TABLES

TABLE 1               MARKET DRIVERS: IMPACT ANALYSIS  42
TABLE 2               MARKET RESTRAINTS: IMPACT ANALYSIS
TABLE 3               MARKET OPPORTUNITIES: IMPACT ANALYSIS
TABLE 4               MARKET CHALLENGES: IMPACT ANALYSIS
TABLE 5               CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 6               CANCER/TUMOR PROFILING MARKET FOR IMMUNOASSAYS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 7               CANCER/TUMOR PROFILING MARKET FOR NEXT-GENERATION SEQUENCING,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 8               CANCER/TUMOR PROFILING MARKET FOR POLYMERASE CHAIN REACTION,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 9               CANCER/TUMOR PROFILING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10             CANCER/TUMOR PROFILING MARKET FOR MICROARRAYS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 11             CANCER/TUMOR PROFILING MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 12             CANCER/TUMOR PROFILING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 13             CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 14             CANCER/TUMOR PROFILING MARKET FOR BREAST CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 15             CANCER/TUMOR PROFILING MARKET FOR LUNG CANCER, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 16             CANCER/TUMOR PROFILING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 17             CANCER/TUMOR PROFILING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 18             CANCER/TUMOR PROFILING MARKET FOR MELANOMA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 19             CANCER/TUMOR PROFILING MARKET FOR OTHER CANCERS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 20             CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 21             CANCER/TUMOR PROFILING MARKET FOR GENETIC BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 22             CANCER/TUMOR PROFILING MARKET FOR PROTEIN BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 23             CANCER/TUMOR PROFILING MARKET FOR OTHER BIOMARKERS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 24             CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 25             CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 26             CANCER/TUMOR PROFILING MARKET FOR BIOMARKER DISCOVERY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 27             CANCER/TUMOR PROFILING MARKET FOR PERSONALIZED MEDICINE,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 28             CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 29             CANCER/TUMOR PROFILING MARKET FOR DIAGNOSTICS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 30             CANCER/TUMOR PROFILING MARKET FOR PROGNOSTICS, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 31             CANCER/TUMOR PROFILING MARKET FOR MONITORING & TREATMENT,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 32             CANCER/TUMOR PROFILING MARKET FOR SCREENING, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 33             CANCER/TUMOR PROFILING MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 34             NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 35             NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 36             NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 37             NORTH AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 38             NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 39             NORTH AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 101
TABLE 40             US: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 41             US: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 42             US: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 43             US: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 44             US: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 45             CANADA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 46             CANADA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 47             CANADA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 48             CANADA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 49             CANADA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 50             EUROPE: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 51             EUROPE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 52             EUROPE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 53             EUROPE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 54             EUROPE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 55             EUROPE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 56             GERMANY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 57             GERMANY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 58             GERMANY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 59             GERMANY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 60             GERMANY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 61             UK: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 62             UK: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 63             UK: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 64             UK: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 65             UK: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 66             FRANCE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 67             FRANCE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 68             FRANCE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 69             FRANCE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 70             FRANCE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 71             ITALY: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 72             ITALY: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 73             ITALY: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 74             ITALY: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 75             ITALY: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 76             SPAIN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 77             SPAIN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 78             SPAIN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 79             SPAIN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 80             SPAIN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 81             ROE: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 82             ROE: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 83             ROE: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 84             ROE: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 85             ROE: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 86             ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 87             ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 88             ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 89             ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 90             ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 91             ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 135
TABLE 92             JAPAN: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 93             JAPAN: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 94             JAPAN: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 95             JAPAN: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 96             JAPAN: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 97             CHINA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 98             CHINA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 99             CHINA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 100          CHINA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 101          CHINA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 102          INDIA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 103          INDIA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 104          INDIA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 105          INDIA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 106          INDIA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 107          ROAPAC: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 108          ROAPAC: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 109          ROAPAC: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2017–2024 (USD MILLION)
TABLE 110          ROAPAC: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 111          ROAPAC: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS,
BY TYPE, 2017–2024 (USD MILLION)
TABLE 112          LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2017–2024 (USD MILLION)
TABLE 113          LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2017–2024 (USD MILLION)
TABLE 114          LATIN AMERICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 115          LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 116          LATIN AMERICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION) 150
TABLE 117          MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY, 2017–2024 (USD MILLION)
TABLE 118          MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE, 2017–2024 (USD MILLION)
TABLE 119          MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE, 2017–2024 (USD MILLION)
TABLE 120          MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)
TABLE 121          MIDDLE EAST & AFRICA: CANCER/TUMOR PROFILING MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2017–2024 (USD MILLION)

LIST OF FIGURES

FIGURE 1             CANCER/TUMOR PROFILING MARKET  20
FIGURE 2             RESEARCH DESIGN
FIGURE 3             BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS,
AND REGION
FIGURE 4             BOTTOM-UP APPROACH
FIGURE 5             TOP-DOWN APPROACH
FIGURE 6             DATA TRIANGULATION METHODOLOGY  28
FIGURE 7             CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY,
2019 VS. 2024 (USD MILLION)
FIGURE 8             CANCER/TUMOR PROFILING MARKET, BY CANCER TYPE,
2019 VS. 2024 (USD MILLION)
FIGURE 9             CANCER/TUMOR PROFILING MARKET, BY BIOMARKER TYPE,
2019 VS. 2024 (USD MILLION)
FIGURE 10          CANCER/TUMOR PROFILING MARKET, BY APPLICATION,
2019 VS. 2024 (USD MILLION)
FIGURE 11          GEOGRAPHICAL SNAPSHOT OF THE CANCER/TUMOR PROFILING MARKET
FIGURE 12          INCREASING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
FIGURE 13          CHINA TO REGISTER THE HIGHEST GROWTH IN THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD   36
FIGURE 14          APAC TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST
PERIOD (2019–2024)
FIGURE 15          DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN
2019 & 2024
FIGURE 16          CANCER/TUMOR PROFILING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 17          GLOBAL CANCER INCIDENCE, 2008–2030
FIGURE 18          LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008–2016
FIGURE 19          INCREASING USE OF INTEGRATED OMICS DATA AND GROWING FOCUS ON LIQUID BIOPSY TESTS ARE KEY MARKET TRENDS
FIGURE 20          IMMUNOASSAYS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 21          BREAST CANCER SEGMENT TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 22          GLOBAL LUNG CANCER INCIDENCE, 2012-2030
FIGURE 23          COLORECTAL CANCER INCIDENCE RATE, KEY COUNTRIES (2018)
FIGURE 24          GENETIC BIOMARKERS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 25          RESEARCH APPLICATIONS TO DOMINATE THE CANCER/TUMOR PROFILING MARKET DURING THE FORECAST PERIOD
FIGURE 26          CANCER/TUMOR PROFILING MARKET: GEOGRAPHIC SNAPSHOT (2018)
FIGURE 27          NORTH AMERICA: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 28          EUROPE: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 29          ASIA PACIFIC: CANCER/TUMOR PROFILING MARKET SNAPSHOT
FIGURE 30          ILLUMINA, INC.: COMPANY SNAPSHOT (2018)
FIGURE 31          QIAGEN N.V.: COMPANY SNAPSHOT (2018)
FIGURE 32          NEOGENOMIC LABORATORIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 33          SYSMEX CORPORATION: COMPANY SNAPSHOT (2018)
FIGURE 34          HTG MOLECULAR DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2018)
FIGURE 35          GENOMIC HEALTH, INC.: COMPANY SNAPSHOT (2018)
FIGURE 36          NANOSTRING TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2018)
FIGURE 37          GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2018)
FIGURE 38          FOUNDATION MEDICINE: COMPANY SNAPSHOT (2018)




掲載企業リスト

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。